Following the description of the immunoglobulin PD-1’s involvement in programmed cell death in 1992 and the subsequent use of cancer-specific monoclonal antibody rituximab for CD20 B cell non-Hodgkin lymphoma in 1997, immunotherapies have carved out a niche among cancer treatment protocols [39,40,41]. This evidence concerns the gene PDCD1 and cancer.